These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36871111)

  • 21. Bayesian single-to-double arm transition design using both short-term and long-term endpoints.
    Xu T; Shi H; Lin R
    Pharm Stat; 2023; 22(4):588-604. PubMed ID: 36755420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bayesian optimal phase II clinical trial design with time-to-event endpoint.
    Zhou H; Chen C; Sun L; Yuan Y
    Pharm Stat; 2020 Nov; 19(6):776-786. PubMed ID: 32524679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
    Ursprung S; Mossop H; Gallagher FA; Sala E; Skells R; Sipple JAN; Mitchell TJ; Chhabra A; Fife K; Matakidou A; Young G; Walker A; Thomas MG; Ortuzar MC; Sullivan M; Protheroe A; Oades G; Venugopal B; Warren AY; Stone J; Eisen T; Wason J; Welsh SJ; Stewart GD
    BMC Cancer; 2021 Nov; 21(1):1238. PubMed ID: 34794412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
    Wason JM; Trippa L
    Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design.
    Morita S; Sakamoto J
    Pharm Stat; 2006; 5(2):109-18. PubMed ID: 17080767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bayesian single-arm phase II trial designs with time-to-event endpoints.
    Wu J; Pan H; Hsu CW
    Pharm Stat; 2021 Nov; 20(6):1235-1248. PubMed ID: 34085764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma.
    Trippa L; Lee EQ; Wen PY; Batchelor TT; Cloughesy T; Parmigiani G; Alexander BM
    J Clin Oncol; 2012 Sep; 30(26):3258-63. PubMed ID: 22649140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug.
    Berry SM; Spinelli W; Littman GS; Liang JZ; Fardipour P; Berry DA; Lewis RJ; Krams M
    Clin Trials; 2010 Apr; 7(2):121-35. PubMed ID: 20338905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design issues in randomized phase II/III trials.
    Korn EL; Freidlin B; Abrams JS; Halabi S
    J Clin Oncol; 2012 Feb; 30(6):667-71. PubMed ID: 22271475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
    Shan G; Zhang H; Jiang T
    BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Re-formulating Gehan's design as a flexible two-stage single-arm trial.
    Grayling MJ; Mander AP
    BMC Med Res Methodol; 2019 Jan; 19(1):22. PubMed ID: 30691398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bayesian adaptive designs for multi-arm trials: an orthopaedic case study.
    Ryan EG; Lamb SE; Williamson E; Gates S
    Trials; 2020 Jan; 21(1):83. PubMed ID: 31937341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
    Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
    Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
    Schlesselman JJ; Reis IM
    Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A predictive probability design for phase II cancer clinical trials.
    Lee JJ; Liu DD
    Clin Trials; 2008; 5(2):93-106. PubMed ID: 18375647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
    Johnson VE; Cook JD
    Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia.
    Yap C; Pettitt A; Billingham L
    BMC Med Res Methodol; 2013 Jul; 13():87. PubMed ID: 23819695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach.
    Cellamare M; Sambucini V
    Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.